Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 19/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 19/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 11/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 9/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pumaprazole SCHEMBL29493303 | 0.91 | CYP3A4 (0.69) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| Pumaprazole SCHEMBL451376 | 0.91 | CYP3A4 (0.69) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL1816224 | 0.91 | CYP3A4 (0.48) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL8892144 | 0.91 | CYP3A4 (0.48) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL7503350 | 0.90 | CYP3A4 (0.60) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL1812546 | 0.90 | CYP3A4 (0.68) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| Hydrochloric Acid SCHEMBL8804655 | 0.90 | CYP3A4 (0.59) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL7828059 | 0.89 | CYP3A4 (0.47) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL6379573 | 0.89 | CYP3A4 (0.58) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL6379721 | 0.88 | CYP3A4 (0.57) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0841904-B1 | ORAL PHARMACEUTICAL COMPOSITIONS WITH DELAYED RELEASE OF REVERSIBLE PROTON PUMP INHIBITORS | ALTANA PHARMA AG (DE) | 2003-02-05 | — | — | EP | claimed |
| EP-0723544-B1 | ALKOXY ALKYL CARBAMATES OF IMIDAZO[1,2-a]PYRIDINES | BYK GULDEN LOMBERG CHEM FAB (DE) | 2001-04-18 | — | — | EP | claimed |
| US-6132768-A | FOR TREATING DISORDERS CAUSED BY HELICOBACTER | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-10-17 | — | — | US | claimed |
| EP-0841904-A1 | ORAL PHARMACEUTICAL COMPOSITIONS WITH DELAYED RELEASE OF REVERSIBLE PROTON PUMP INHIBITORS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1998-05-20 | — | — | EP | claimed |
| US-5719161-A | REACTING AN IMIDAZO(1,2-A)PYRIDINE WITH A PHENYLCARBAMATE; USEFUL IN THE TREATMENT OF GASTROINTESTINAL DISEASES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-02-17 | — | — | US | claimed |
| WO-1997002021-A1 | ORAL PHARMACEUTICAL COMPOSITIONS WITH DELAYED RELEASE OF REVERSIBLE PROTON PUMP INHIBITORS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1997-01-23 | — | — | WO | claimed |
| US-7951398-B2 | Pharmaceutical preparation comprising an active dispersed on a matrix | NYCOMED GMBH (DE) | 2011-05-31 | — | — | US | disclosed |
| US-20090048287-A1 | Compositions useful for treating gastrointestinal motility disorders | EDUSA PHARMACEUTICALS, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20070122474-A1 | Pharmaceutical preparation comprising an active dispersed on a matrix | ALTANA PHARMA AG | 2007-05-31 | — | — | US | disclosed |
| US-7175854-B2 | Pharmaceutical preparation comprising an active dispersed on a matrix | ALTANA PHARMA AG (DE) | 2007-02-13 | — | — | US | disclosed |
| US-20060189648-A1 | Compositions useful for increasing lower esophageal sphincter pressure | EDUSA PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| EP-1663313-A2 | COMPOSITIONS USEFUL FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | Dynogen Pharmaceuticals Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050059704-A1 | Compositions useful for treating gastrointestinal motility disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| EP-0841904-B1 | ORAL PHARMACEUTICAL COMPOSITIONS WITH DELAYED RELEASE OF REVERSIBLE PROTON PUMP INHIBITORS | ALTANA PHARMA AG (DE) | 2003-02-05 | — | — | EP | disclosed |
| WO-2002045693-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA PHARMA AG (DE) | 2002-06-13 | — | — | WO | disclosed |
| EP-0723544-B1 | ALKOXY ALKYL CARBAMATES OF IMIDAZO[1,2-a]PYRIDINES | BYK GULDEN LOMBERG CHEM FAB (DE) | 2001-04-18 | — | — | EP | disclosed |
| US-6132768-A | FOR TREATING DISORDERS CAUSED BY HELICOBACTER | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-10-17 | — | — | US | disclosed |
| US-5719161-A | REACTING AN IMIDAZO(1,2-A)PYRIDINE WITH A PHENYLCARBAMATE; USEFUL IN THE TREATMENT OF GASTROINTESTINAL DISEASES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-02-17 | — | — | US | disclosed |
| EP-0723544-A1 | ALKOXY ALKYL CARBAMATES FROM IMIDAZO (1,2-a)PYRIDINES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1996-07-31 | — | — | EP | disclosed |
| WO-1995010518-A1 | ALKOXY ALKYL CARBAMATES FROM IMIDAZO (1,2-a)PYRIDINES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1995-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048287-A1 | Compositions useful for treating gastrointestinal motility disorders | HRH2, MLNR, HTR3A | CYP3A4 1306/4885CYP2C9 1083/4885CYP2D6 620/4885 |
| US-20050059704-A1 | Compositions useful for treating gastrointestinal motility disorders | HRH2, MLNR, HTR3A | CYP3A4 1306/4885CYP2C9 1083/4885CYP2D6 620/4885 |
| US-20060189648-A1 | Compositions useful for increasing lower esophageal sphincter pressure | HTR3A, HTR3D, HTR3B | CYP3A4 2764/4885CYP2C9 2333/4885CYP2D6 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.